Oppenheimer Maintains Outperform on Seagen, Raises Price Target to $229
Oppenheimer analyst Jay Olson maintains Seagen (NASDAQ:SGEN) with a Outperform and raises the price target from $210 to $229.
Did Elon Musk Just Put His Skepticism Behind And Warm Up To mRNA Tech That Powers Most COVID-19 Vaccines?
Tesla CEO Elon Musk has been a skeptic of the COVID-19 vaccines and highly critical of Dr.
JMP Securities Downgrades Seagen to Market Perform
JMP Securities analyst Reni Benjamin downgrades Seagen (NASDAQ:SGEN) from Market Outperform to Market Perform.
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash.
Evercore ISI Group Downgrades Seagen to In-Line, Raises Price Target to $229
Evercore ISI Group analyst Joshua Schimmer downgrades Seagen (NASDAQ:SGEN) from Outperform to In-Line and raises the price target from $175 to $229.
Seagen’s $43B Deal To Double Pfizer’s Early-Stage Oncology Pipeline, Seagen Says Is Right Step
Pfizer Inc (NYSE:PFE) has agreed to acquire Seagen Inc (NASDAQ:SGEN) for $229 in cash per Seagen share for a total enterprise value…
Pfizer Is Sending Seagen Stock Soaring Monday: What’s Going On?
Seagen Inc (NASDAQ: SGEN) shares are trading higher Monday after Pfizer Inc (NYSE: PFE) announced plans to acquire the global biotech company.
Needham Maintains Buy on Seagen, Raises Price Target to $185
Needham analyst Ami Fadia maintains Seagen (NASDAQ:SGEN) with a Buy and raises the price target from $178 to $185.
Here’s How Much You Would Have Made Owning Seagen Stock In The Last 5 Years
Seagen (NASDAQ:SGEN) has outperformed the market over the past 5 years by 18.55% on an annualized basis producing…